‘Trojan Horse’ Obesity Drug Supercharges Weight Loss by Sneaking Active Cargo Directly Into Cells
Researchers have unveiled a new “Trojan horse” obesity drug that dramatically amplifies weight loss and blood sugar control in early tests, potentially redefining how metabolic diseases like type 2 diabetes are treated.
In a preclinical study published in Nature, a team led by metabolism expert Prof. Timo D. Müller at Helmholtz Munich designed a hybrid molecule that hijacks the body’s own cellular machinery. The compound uses the well-known GLP-1/GIP signalling pathway as an entry point—then, once inside, delivers a secondary metabolic compound directly where it is needed.
The result? In laboratory tests, mice treated with the new agent ate less food, shed significantly more weight, and achieved superior blood-glucose control compared to standard treatments.
Beyond Current GLP...